Stocks of Xeris Biopharma Holdings Inc (NASDAQ:XERS) traded higher last session on Wall Street, up 5.56% to $5.51.
XERS stock price is now 45.20% away from the 50-day moving average and 80.10% away from the 200-day moving average. The market capitalization of the company currently stands at $848.21M.
With the price target maintained at $3, Piper Sandler recently Downgraded its rating from Overweight to Neutral for Xeris Biopharma Holdings Inc (NASDAQ: XERS). On March 28, 2024, Oppenheimer recently initiated its ‘Outperform’ rating on the stock quoting a target price of $5, while ‘Craig Hallum’ rates the stock as ‘Buy’
In other news, Schmid John P., Director bought 4,515 shares of the company’s stock on Aug 12 ’24. The stock was bought for $10,147 at an average price of $2.25. Upon completion of the transaction, the Director now directly owns 25,200 shares in the company, valued at $0.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 09 ’24, Director Schmid John P. bought 4,285 shares of the business’s stock. A total of $10,134 was incurred on buying the stock at an average price of $2.37. This leaves the insider owning 20,685 shares of the company worth $0.11 million. A total of 7.76% of the company’s stock is owned by insiders.
During the past 12 months, Xeris Biopharma Holdings Inc has had a low of $1.69 and a high of $5.23. The fifty day moving average price for XERS is $3.7948 and a two-hundred day moving average price translates $3.05945 for the stock.
The latest earnings results from Xeris Biopharma Holdings Inc (NASDAQ: XERS) was released for 2024-12-31. The net profit margin was -27.00% and return on equity was -617.16% for XERS. The company reported revenue of $60.1 million for the quarter, compared to $44.39 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 35.39 percent.
